Sandoz Partners With Fresenius Unit mAbxience On Licensing, Development, Manufacturing And Commercialization For An Emicizumab Biosimilar Candidate

Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.

Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - 2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities

The bone metastasis in solid tumors market is expected to expand from 2026-2036 across seven major markets, driven by rising cancer survival rates, improved diagnostics, and growing demand for targeted therapies and radiopharmaceuticals. The market is characterized by established treatments like denosumab and zoledronic acid, with emerging therapies including cabozantinib and radioligand treatments. Key unmet needs include limited disease-modifying therapies, persistent skeletal complications, and lack of validated biomarkers for treatment selection.

Henlius And Sandoz Enter Strategic Collaboration Covering Up To 10 Proposed Biosimilar Assets, Expanding Their 2025 Oncology Partnership

Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.